Fisiopatologia della PAH
-
Upload
guch-piemonte -
Category
Documents
-
view
137 -
download
1
description
Transcript of Fisiopatologia della PAH
![Page 1: Fisiopatologia della PAH](https://reader035.fdocuments.net/reader035/viewer/2022081414/54c902b64a79598e478b4598/html5/thumbnails/1.jpg)
FISIOPATOLOGIA DELLA PAH
Carlo Albera Università di Torino
Facoltà di Medicina San Luigi Gonzaga Dipartimento di Scienze Cliniche e Biologiche
Ambulatorio Interstiziopatie Polmonari / Malattie Rare
![Page 2: Fisiopatologia della PAH](https://reader035.fdocuments.net/reader035/viewer/2022081414/54c902b64a79598e478b4598/html5/thumbnails/2.jpg)
– Actelion – Almirall – Aptalis – Bayer – Centocor – Eli-Lilly – GSK – InterMune, Inc.
2
Dr Carlo Albera has served as investigator in clinical trials, consultant, speaker, Steering Committee or Scientific Advisory Board member for:
![Page 3: Fisiopatologia della PAH](https://reader035.fdocuments.net/reader035/viewer/2022081414/54c902b64a79598e478b4598/html5/thumbnails/3.jpg)
Ipertensione arteriosa polmonare
• Malattia rara o associata a malattie rare
• Elevata resistenza delle arterie polmonari
• Invalidante, progressiva, prognosi infausta
• Gestione in ambito multidisciplinare
• Disponibili linee guida
• Terapia efficace (alti costi)
![Page 4: Fisiopatologia della PAH](https://reader035.fdocuments.net/reader035/viewer/2022081414/54c902b64a79598e478b4598/html5/thumbnails/4.jpg)
Anatomy of the pulmonary acinus
Smooth muscle cells
Contractile intermediate cells
and pericytes (intima)
From Olschewski H, Seeger W , 2002 Modif
![Page 5: Fisiopatologia della PAH](https://reader035.fdocuments.net/reader035/viewer/2022081414/54c902b64a79598e478b4598/html5/thumbnails/5.jpg)
Caratteristiche del circolo polmonare
• Bassa pressione • Flusso elevato • Grande possibilità di reclutamento
di vasi normalmente non perfusi
Ø Bassa pressione transmurale Ø Arterie con parete sottile
![Page 6: Fisiopatologia della PAH](https://reader035.fdocuments.net/reader035/viewer/2022081414/54c902b64a79598e478b4598/html5/thumbnails/6.jpg)
Ipertensione arteriosa polmonare • Malattie delle piccole arterie polmonari
• Ispessimento parete / riduzione lume • Aumento delle resistenze vascolari
Ø Aumento del post-carico del ventricolo dx Ø Insufficienza ventricolare dx per incapacità di tollerare l’aumento del post-carico
![Page 7: Fisiopatologia della PAH](https://reader035.fdocuments.net/reader035/viewer/2022081414/54c902b64a79598e478b4598/html5/thumbnails/7.jpg)
Progressione temporale della PAH
![Page 8: Fisiopatologia della PAH](https://reader035.fdocuments.net/reader035/viewer/2022081414/54c902b64a79598e478b4598/html5/thumbnails/8.jpg)
From Olschewski H, Seeger W , 2002 Modif
Causes of precapillary pulmonary hypertension
![Page 9: Fisiopatologia della PAH](https://reader035.fdocuments.net/reader035/viewer/2022081414/54c902b64a79598e478b4598/html5/thumbnails/9.jpg)
Rimodellamento della parete vascolare
• Eterogeneità delle componenti strutturali della parete vascolare
• Tutte sono coinvolte nel processo di rimodellamento
![Page 10: Fisiopatologia della PAH](https://reader035.fdocuments.net/reader035/viewer/2022081414/54c902b64a79598e478b4598/html5/thumbnails/10.jpg)
Rimodellamento della parete vascolare : concetti di fondo
• Alterazioni funzionali • Alterazioni strutturali Ø Vasi di piccolo Ø : - evento precoce
Ø Vasi di grande Ø : - evento tardivo
- conseguenza del sovraccarico pressorio
Progressione anatomica
![Page 11: Fisiopatologia della PAH](https://reader035.fdocuments.net/reader035/viewer/2022081414/54c902b64a79598e478b4598/html5/thumbnails/11.jpg)
Rimodellamento vascolare : muscolarizzazione delle arterie polmonari non
muscolari • Comparsa di uno strato di cellule muscolari
lisce nella parete delle arterie intra-acinari
• Vasi precapillari – Le cellule intermedie della lamina elastica interna
proliferano ed assumono il fenotipo delle SMC
• Vasi più distali (Ø 20-30µm; no lamina elastica) – Periciti e Fibroblasti interstiziali vengono
reclutati ed assumono il fenotipo delle SMC
![Page 12: Fisiopatologia della PAH](https://reader035.fdocuments.net/reader035/viewer/2022081414/54c902b64a79598e478b4598/html5/thumbnails/12.jpg)
Rimodellamento vascolare : aumento della muscolarizzazione delle arterie
polmonari muscolari
• L’incremento pressorio derivante dalla vasocostrizione e dal rimodellamento periferico provoca nelle arterie di medio Ø proliferazione ed ipertrofia delle cellule muscolari lisce (-> riduzione fissa del Ø)
• Media – Incremento della componente elastica – Deposizione di collagene di tipo I • Avventizia – Incremento dei fibroblasti – Deposizione di collagene
Il danno / attivazione dell’endotelio porta ad un passaggio di proteine plasmatiche: l’elastasi danneggia la lamine
elastica e promuove le modificazioni di media ed avventizia
![Page 13: Fisiopatologia della PAH](https://reader035.fdocuments.net/reader035/viewer/2022081414/54c902b64a79598e478b4598/html5/thumbnails/13.jpg)
Rimodellamento vascolare : formazione della “neointima”
• Fenomeno tipico della grave PAH (IPAH, da cardiopatia)
• Avviene nelle arterie di ogni Ø
• Non costituisce una risposta specifica
Origine dei miofibroblasti:
• Transdifferenziazione delle cellule endoteliali
• Migrazione di cellule “smooth muscle-like” dalla media
• Migrazione dei fibroblasti dell’avventizia
![Page 14: Fisiopatologia della PAH](https://reader035.fdocuments.net/reader035/viewer/2022081414/54c902b64a79598e478b4598/html5/thumbnails/14.jpg)
Ipertensione arteriosa polmonare
§ Malattie delle piccole arterie polmonari § Ispessimento parete / riduzione lume § Aumento delle resistenze vascolari
Ø Aumento del post-carico del ventricolo destro Ø Insufficienza ventricolare destra per incapacità di tollerare l’aumento del post-carico
![Page 15: Fisiopatologia della PAH](https://reader035.fdocuments.net/reader035/viewer/2022081414/54c902b64a79598e478b4598/html5/thumbnails/15.jpg)
Rimodellamento vascolare : lesioni plessiformi
• Solo nelle forme di grave PAH • 80% IPAH • PAH secondaria grave • Originano da arterie di 200-400 µm Ø • Sono “tubi” endoteliali sostenuti da uno stroma (proteine di matrice e miofibroblasti) • Le cellule endoteliali sono VEGF e VEGFr + • Nella IPAH sono monoclonali • Emodinamicamente irrilevanti • Sono marker della anomala risposta endoteliale
![Page 16: Fisiopatologia della PAH](https://reader035.fdocuments.net/reader035/viewer/2022081414/54c902b64a79598e478b4598/html5/thumbnails/16.jpg)
Modificazioni cellulari nel rimodellamento vascolare : cellule endoteliali
• Caratteristiche fisiologiche: – Barriera semipermeabile – Antritrombigena
• Possiede proprietà metaboliche che influenzano: – Tono vascolare – Crescita cellulare – Differenziazione cellulare – Risposta a stimoli lesivi
• Ipossia • Aumento del flusso • Flogosi • Sostanze tossiche • Fattori genetici
Stimoli diversi evocano risposte in parte
differenti
![Page 17: Fisiopatologia della PAH](https://reader035.fdocuments.net/reader035/viewer/2022081414/54c902b64a79598e478b4598/html5/thumbnails/17.jpg)
Modificazioni fisiopatologiche nel rimodellamento vascolare : endotelio e coagulazioe
Alterazioni che causano PAH attraverso:
• CTEPH – Emboli dal circolo venoso sistemico – Rimodellamento in situ con parziale ricanalizzazione
• Trombosi in situ – Lesioni endoteliali mediate dalla trombina – Trasudazione di proteine – Edema interstiziale – Stimolo a proliferazione fibroblasti e sintesi
matrice – Aumento aderenza PMNs all’endotelio
I PRODOTTI DI DEGRADAZIONE DEL FIBRINOGENO SONO DA TEMPO NOTI COME FATTORI DI CRESCITA PER I
FIBROBLASTI
![Page 18: Fisiopatologia della PAH](https://reader035.fdocuments.net/reader035/viewer/2022081414/54c902b64a79598e478b4598/html5/thumbnails/18.jpg)
Modificazioni cellulari nel rimodellamento vascolare : risposta delle cellule endoteliali a differenti stimoli
• Ipossia : – Proliferazione cellule endoteliali
• Shear stress (15 dyn/cm2): Produzione/rilascio dall’endotelio di mediatori
vasoattivi – ET-1 – Angiotensina II – Trombossano – NO – Prostaciclina E di fattori di crescita – PDGF – TGF-β
![Page 19: Fisiopatologia della PAH](https://reader035.fdocuments.net/reader035/viewer/2022081414/54c902b64a79598e478b4598/html5/thumbnails/19.jpg)
Ipertrofia della tonaca media
Arteria pre-acinare Arteria intra-acinare
![Page 20: Fisiopatologia della PAH](https://reader035.fdocuments.net/reader035/viewer/2022081414/54c902b64a79598e478b4598/html5/thumbnails/20.jpg)
Isspessimento dell’intima
Laminare concentrico arteria pre-acinare
Laminare concentrico arteria intra-acinare
SMA+ cells
![Page 21: Fisiopatologia della PAH](https://reader035.fdocuments.net/reader035/viewer/2022081414/54c902b64a79598e478b4598/html5/thumbnails/21.jpg)
Isspessimento dell’intima
Laminare eccentrico arteria pre -acinare
Non laminare eccentrico arteria pre-acinare
![Page 22: Fisiopatologia della PAH](https://reader035.fdocuments.net/reader035/viewer/2022081414/54c902b64a79598e478b4598/html5/thumbnails/22.jpg)
Lesioni plessiformi
Arteria intra-acinare Arteria pre-acinare adiacente a lesione plessiforme
SMA- endothelial cells SMA- endothelial cells
Dilation lesions
![Page 23: Fisiopatologia della PAH](https://reader035.fdocuments.net/reader035/viewer/2022081414/54c902b64a79598e478b4598/html5/thumbnails/23.jpg)
Altre lesioni
Lesione “colander-like” Lesione infiammatoria tipo arterite linfomonocitaria
![Page 24: Fisiopatologia della PAH](https://reader035.fdocuments.net/reader035/viewer/2022081414/54c902b64a79598e478b4598/html5/thumbnails/24.jpg)
Factors stmulatig cell proliferation and collagen synthesis
Smooth muscle cell growth
• IGF-1, IGF-2 • PDGF • EGF • bFGF, aFGF • Insulin • Heparin • TX A2 • ET-1 • Angiotensin II • Serotonin • Tenascin • Leukotriens • ROS
Type 1 collagen synthesis • IGF-1, IGF-2 • TGF-β • PDGF • Angiotensin II • Tenascin
![Page 25: Fisiopatologia della PAH](https://reader035.fdocuments.net/reader035/viewer/2022081414/54c902b64a79598e478b4598/html5/thumbnails/25.jpg)
Factors inhibiting cell proliferation and collagen synthesis
Smooth muscle cell growth
• TGF-βBMPS • IL-1 • Prostaglandins • Interferons • TNF-α • Heparin sulfates • NO • CO • Adrenomedullin • ANP • Isoproterenol
Type 1 collagen synthesis • Prostaglandins
• Interferons
• NO • ANP
![Page 26: Fisiopatologia della PAH](https://reader035.fdocuments.net/reader035/viewer/2022081414/54c902b64a79598e478b4598/html5/thumbnails/26.jpg)
Definizione di Ipertensione Polmonare
Ipertensione Polmonare (PH) § Condizione emodinamica e fisiopatologica
caratterizzata da aumento della pressione polmonare media a riposo ≥ 25 mmHg (RHC) riscontrabile in molteplici condizioni cliniche
Ipertensione Arteriosa Polmonare (PAH) * § Condizione clinica caratterizzata da Ipertensione
Polmonare Precapillare (Wedge Pressure RHC < 15 mmHg) in assenza di cause note
(*) In pratica incluse solo le forme del gruppo 1, anche se nella maggior parte degli altri gruppi la PH è comunque precapillare
![Page 27: Fisiopatologia della PAH](https://reader035.fdocuments.net/reader035/viewer/2022081414/54c902b64a79598e478b4598/html5/thumbnails/27.jpg)
Hemodynamic progression of PAH
Pulm. pressure
Cardiac output
Pulm
onar
y A
rter
y Pr
essu
re
Time
Years Months
Therapeutic window
RV function
NYHA I: No limits to
physical activity NYHA II Some limitation
NYHA IV Severe limitation
Symtoms at rest
NYHA III Marked limitation
Survival,QO
L
![Page 28: Fisiopatologia della PAH](https://reader035.fdocuments.net/reader035/viewer/2022081414/54c902b64a79598e478b4598/html5/thumbnails/28.jpg)
Manifestazioni cliniche • Dispnea • Ridotta tolleranza allo sforzo • Astenia • Dolore toracico • Edemi • Cardiopalmo • Vertigini • Sincope • Morte improvvisa
![Page 29: Fisiopatologia della PAH](https://reader035.fdocuments.net/reader035/viewer/2022081414/54c902b64a79598e478b4598/html5/thumbnails/29.jpg)
§ PAH is often asymptomatic in its early stages § Symptoms are often nonspecific, leading to an
initial effort to diagnose or exclude more common conditions. 35% are misdiagnosed at first presentation.
§ Patients with PAH typically face a lag time from onset of symptoms to diagnosis of approx 2 years.
§ PAH is frequently associated with comorbid conditions, further complicating diagnosis
§ In patients with suspected PAH, right heart catheterization (RHC) is required to confirm the diagnosis
A DIFFICULT DIAGNOSIS
![Page 30: Fisiopatologia della PAH](https://reader035.fdocuments.net/reader035/viewer/2022081414/54c902b64a79598e478b4598/html5/thumbnails/30.jpg)
Significant numbers of PAH patients have co-morbidities
N=1226
1. Elliott GC et al. Chest 2007; 631S.
Over half of patients enrolled in the study had two or more
co-morbid conditions
![Page 31: Fisiopatologia della PAH](https://reader035.fdocuments.net/reader035/viewer/2022081414/54c902b64a79598e478b4598/html5/thumbnails/31.jpg)
DISTRIBUTION OF THE TYPE OF PAH
Humbert M et al Am J Resp Crit Care Med 2006; 173: 1023–1030
iPAH 39,2%
FPAH 3,9%
Anorex 9,5%
CTD 15,3%
CHD 11,3%
PoHT 10,4%
HIV 6,2%
PAH is a rare disease: prevalence is between 15–25 cases/million PAH is rapidly evolving
ü 75% NYHA FC III at diagnosis ü Median survival of IPAH is 2.8 years
![Page 32: Fisiopatologia della PAH](https://reader035.fdocuments.net/reader035/viewer/2022081414/54c902b64a79598e478b4598/html5/thumbnails/32.jpg)
32
Gibbs J. Eur Respir. Rev. 2007; 16; 8-12
Prognosi della Ipertensione Arteriosa Polmonare
L’aspettativa media di vita dal momento della diagnosi ed in assenza di terapia è:
2,8 anni nell’adulto
10 mesi nei bambini
![Page 33: Fisiopatologia della PAH](https://reader035.fdocuments.net/reader035/viewer/2022081414/54c902b64a79598e478b4598/html5/thumbnails/33.jpg)
![Page 34: Fisiopatologia della PAH](https://reader035.fdocuments.net/reader035/viewer/2022081414/54c902b64a79598e478b4598/html5/thumbnails/34.jpg)
Clinical Classification of Pulmonary Hypertension (Dana Point 2008)
3. PH due to lung dis/hypoxiaemia 3.1 COPD 3.2 ILD 3.3 Other pulmonary diseases with mixed
restrictive and obstructive pattern 3.4 Sleep-disordered breathing 3.5 Alveolar hypoventilation disorders 3.6 Chronic exposure to high altitude 3.7 Developmental abnormabilities
4. Chronic thromboembolic PH
2. PH due to left heart disease 2.1 Systolic dysfunction 2.2 Diastolic dysfunction 2.3 Valvular diseases
1’. PVOD and/or Pulm capill Haemang.
1. Pulmonary Arterial Hypertension 1.1 Idiopatic 1.2 Heritable
1.2.1 BMPR2 1.2.2 ALK1, endoglin (with or without hereditary haemorrhaigc teleangectasia)
1.2.3 Unknown 1.3 Drugs and toxins induced 1.4 Associated with (APAH)
1.4.1 Connective Tissue Diseases 1.4.2 HIV infection 1.4.3 Portal hypertension 1.4.4 Congenital heart disease 1.4.5 Schistosomiasis 1.4.6 Chronic haemolityc anaemia
1.5 Persistent PH of the newborn
5. PH with unclear and/or multifact mechs 5.1 Haematological dis: myieloproliferative,
splenectomy 5.2 Systemic dis: sarcoidosis, pulmonary
Langerhans cell histiocytosis, lymphangioleiomyomatosis
5.3 Metabolic dis: glycogen storage disease. Gaucher disease, thyroid disorders
5.4 Others: tumoral obstruction, fibrosing mediastinitis, CRF on dialysis
3
1
2
![Page 35: Fisiopatologia della PAH](https://reader035.fdocuments.net/reader035/viewer/2022081414/54c902b64a79598e478b4598/html5/thumbnails/35.jpg)
![Page 36: Fisiopatologia della PAH](https://reader035.fdocuments.net/reader035/viewer/2022081414/54c902b64a79598e478b4598/html5/thumbnails/36.jpg)
Echocardiographic evaluation M-mode
- RV free wall motion - TAPSE
Two-dimensional
- RV enlargement/hypertrophy - RA enlargement - pericardial effusion - LV compression
Doppler - PAP - Trans-tricuspid peak velocity
- Trans-tricuspid pressure gradient
Newer approaches
- Myocardial doppler Tissue imaging
- One-dimensional strain
RV: Right ventricular; RA: Right atrial; LV: left ventricular; PAP: Pulmonary artery pressure; TAPSE: Tricuspid annular plane systolic excursion
Ask specifically for right ventricular assessment!
Lindqvist et al. Eur J Echocardiogr 2008 Mar; 9: 225-234
![Page 37: Fisiopatologia della PAH](https://reader035.fdocuments.net/reader035/viewer/2022081414/54c902b64a79598e478b4598/html5/thumbnails/37.jpg)
![Page 38: Fisiopatologia della PAH](https://reader035.fdocuments.net/reader035/viewer/2022081414/54c902b64a79598e478b4598/html5/thumbnails/38.jpg)
a Class of recommendation, b Level of evidence
Recommendations for right heart catheterization
![Page 39: Fisiopatologia della PAH](https://reader035.fdocuments.net/reader035/viewer/2022081414/54c902b64a79598e478b4598/html5/thumbnails/39.jpg)
In conclusion, the clear recent progress in the treatment of PAH supported by the concordant results of recent meta-analyses need to be further extended because the current treatment strategy is still not satisfactory There is no time for sterile discussions about the extent of current achievements based on others’ published papers. Let usfight the battle against PAH ‘on the field’ together. Our patients deserve this commitment.
![Page 40: Fisiopatologia della PAH](https://reader035.fdocuments.net/reader035/viewer/2022081414/54c902b64a79598e478b4598/html5/thumbnails/40.jpg)
European Heart Journal (2010) 31, 2080–2086
![Page 41: Fisiopatologia della PAH](https://reader035.fdocuments.net/reader035/viewer/2022081414/54c902b64a79598e478b4598/html5/thumbnails/41.jpg)
European Heart Journal (2010) 31, 2080–2086
![Page 42: Fisiopatologia della PAH](https://reader035.fdocuments.net/reader035/viewer/2022081414/54c902b64a79598e478b4598/html5/thumbnails/42.jpg)
ERS 21st Annual Congress Amsterdam 24-28 September 2011 Session 185 ,Evening Symposium, Sunday September 25
The 2011 PAH debate: what is the biggest challenge we face to optimize patient outcome?
• To diagnose pa-ents sooner ? • To recognise deteriora-on sooner? • To treat more aggressively ?
![Page 43: Fisiopatologia della PAH](https://reader035.fdocuments.net/reader035/viewer/2022081414/54c902b64a79598e478b4598/html5/thumbnails/43.jpg)
Pulmonary Hypertension Sanjiv J. Shah, MD
JAMA. 2012;308(13):1366-1374.
Pulmonary hypertension (PH), defined as elevated pulmonary artery pressure, is common in the general population and associated with increased mortality. Accordingly, physicians commonly encounter patients with dyspnea, exercise intolerance, and/or right heart failure who have elevated pulmonary artery systolic pressure (PASP) on echocardiography. Although pulmonary arterial vasodilators may often be considered in this setting, these drugs have been predominantly tested in the subset of PH patients with pulmonary arterial hypertension (PAH). Elevated PASP alone is not sufficient for the diagnosis of PAH, and secondary causes of PASP elevation, most commonly left heart disease, are far more prevalent than isolated PAH.
![Page 44: Fisiopatologia della PAH](https://reader035.fdocuments.net/reader035/viewer/2022081414/54c902b64a79598e478b4598/html5/thumbnails/44.jpg)
Pulmonary Hypertension Sanjiv J. Shah, MD
JAMA. 2012;308(13):1366-1374.
Treatment of this more common group of patients with PH due to left heart disease is challenging because there are few evidence-based treatment options, and pulmonary vasodilator therapy may lead to worsening symptoms. Therefore, improving symptoms and avoiding adverse outcomes in patients with PH requires the following: (1) understanding the optimal use of echocardiography for the diagnosis of PH;
(2) recognizing the utility and proper interpretation of invasive hemodynamic testing prior to starting pulmonary vasodilator therapy;
(3) differentiating PAH from pulmonary venous hypertension due to left heart disease; (4) understanding the appropriate treatment strategies for PH and resultant right heart failure.
![Page 45: Fisiopatologia della PAH](https://reader035.fdocuments.net/reader035/viewer/2022081414/54c902b64a79598e478b4598/html5/thumbnails/45.jpg)
![Page 46: Fisiopatologia della PAH](https://reader035.fdocuments.net/reader035/viewer/2022081414/54c902b64a79598e478b4598/html5/thumbnails/46.jpg)
Pulmonary arterial hypertension (PAH) is a rapidly progressive disease, ultimately leading to right heart failure and death. Accumulating evidence indicates that intervention early in disease progression results in better outcomes than delaying treatment. There is still an urgent need for prospective collaborative initiatives to assess novel goals and improve treatment strategies that would allow physicians to personalise and optimise clinical management for their patients with PAH.
![Page 47: Fisiopatologia della PAH](https://reader035.fdocuments.net/reader035/viewer/2022081414/54c902b64a79598e478b4598/html5/thumbnails/47.jpg)
Eur Respir Rev 2012; 21: 123, 40–47
Tools and variables for detecting disease progression
![Page 48: Fisiopatologia della PAH](https://reader035.fdocuments.net/reader035/viewer/2022081414/54c902b64a79598e478b4598/html5/thumbnails/48.jpg)
Eur Respir Rev 2012; 21: 123, 40–47
Variables with established importance for assessing disease severity, stability and prognosis in pulmonary arterialhypertension
![Page 49: Fisiopatologia della PAH](https://reader035.fdocuments.net/reader035/viewer/2022081414/54c902b64a79598e478b4598/html5/thumbnails/49.jpg)
Eur Respir Rev 2012; 21: 123, 40–47
Goal-oriented strategy at the pulmonary hypertension clinic at
Erasme University (Brussels, Belgium)
![Page 50: Fisiopatologia della PAH](https://reader035.fdocuments.net/reader035/viewer/2022081414/54c902b64a79598e478b4598/html5/thumbnails/50.jpg)
Pulmonary hypertension (PH) is a complex, multifactorial disorder divided into five major subtypes according to pathological, pathophysiological and therapeutic characteristics. Although there are distinct differences between the PH categories, a number of processes are common to the pathology of all subtypes. Vasoconstriction, as a result of endothelial dysfunction and an imbalance in the levels of vasoactive mediators, is a well-characterised contributory mechanism. Excessive cell proliferation and impaired apoptosis in pulmonary vessels leading to structural remodelling is most evident in pulmonary arterial hypertension (PAH), and several factors have been implicated, including mitochondrial dysfunction and mutations in bone morphogenetic protein receptor type 2.
![Page 51: Fisiopatologia della PAH](https://reader035.fdocuments.net/reader035/viewer/2022081414/54c902b64a79598e478b4598/html5/thumbnails/51.jpg)
Inflammation plays a key role in the development of PH, with increased levels of many cytokines and chemokines in affected patients. Exciting insights into the role of angiogenesis and bone marrow-derived endothelial progenitor cells in disease progression have also recently been revealed. Furthermore, there is increasing interest in changes in the right ventricle in PH and the role of metabolic abnormalities. Despite considerable progress in our understanding of the molecular mechanisms of PH, further research is required to unravel and integrate the molecular changes into a better understanding of the pathophysiology of PH, particularly in non-PAH, to put us in a better position to use this knowledge for improved treatments.
![Page 52: Fisiopatologia della PAH](https://reader035.fdocuments.net/reader035/viewer/2022081414/54c902b64a79598e478b4598/html5/thumbnails/52.jpg)
Key pathological mechanisms underlying vascular changes in pulmonary hypertension
Eur Respir Rev 2012; 21: 123, 19–26
![Page 53: Fisiopatologia della PAH](https://reader035.fdocuments.net/reader035/viewer/2022081414/54c902b64a79598e478b4598/html5/thumbnails/53.jpg)
Initiatives to develop adult congenital centers dedicated to the care of GUCH patients are warranted, and should include congenital heart surgeons operating in a setting mimicking children’s hospitals.
Ann Thorac Surg 2010 ; 90:573–9
![Page 54: Fisiopatologia della PAH](https://reader035.fdocuments.net/reader035/viewer/2022081414/54c902b64a79598e478b4598/html5/thumbnails/54.jpg)
International Journal of Cardiology 150 (2011) 59–64
Results With the publication of this document the interdisciplinary task force considers its first task as completed. Conclusions The compiled recommendations for the structure of the interdisciplinary medical care of adults with congenital heart disease (GUCH) should ensure that the structural and medical pre-conditions for comprehensive GUCH medical care are created.
![Page 55: Fisiopatologia della PAH](https://reader035.fdocuments.net/reader035/viewer/2022081414/54c902b64a79598e478b4598/html5/thumbnails/55.jpg)
International Journal of Cardiology 150 (2011) 59–64
![Page 56: Fisiopatologia della PAH](https://reader035.fdocuments.net/reader035/viewer/2022081414/54c902b64a79598e478b4598/html5/thumbnails/56.jpg)
International Journal of Cardiology 150 (2011) 59–64